A First in Human, Dose Escalation Study of JAB-3068 ?SHP2 Inhibitor? in Adult Patients With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 30
Summary
- Conditions
- Esophageal Cancer
- Head and Neck Cancer
- Non -Small Cell Lung Cancer
- Other Metastatic Solid Tumors
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03518554
- Collaborators
- Not Provided
- Investigators
- Study Director: Jacobio Pharmaceuticals Jacobio Pharmaceuticals Co., Ltd.
Get Well Soon